ELGN-2112 Clinical Trials
2 recruitingDrug
Phase 31Phase 21
Showing 1–2 of 2 trials
Recruiting
Phase 2
Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
Intestinal Malabsorption
Elgan Pharma Ltd.60 enrolled1 locationNCT05904626
Recruiting
Phase 3
Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
Intestinal Malabsorption
Elgan Pharma Ltd.360 enrolled1 locationNCT05670951